Intuitive Surgical IncFind Ratings Reports
INTUITIVE SURGICAL INC's gross profit margin for the third quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. INTUITIVE SURGICAL INC is extremely liquid. Currently, the Quick Ratio is 5.06 which clearly shows the ability to cover any short-term cash needs. ISRG managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 34.66% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||682.9||589.7|
|Net Income ($mil)||211.0||167.3|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||2215.3||1739.7|
|Total Assets ($mil)||6174.7||4682.3|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||71.31||71.12|
|Return on Assets||11.69||11.65|
|Return on Equity||13.02||13.25|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||38.7||37.3|
|Div / share||0.0||0.0|
|Book value / share||143.2||110.33|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||242811.0||312586.0|
BUY. INTUITIVE SURGICAL INC's P/E ratio indicates a discount compared to an average of 45.75 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 24.75. For additional comparison, its price-to-book ratio of 4.78 indicates a significant premium versus the S&P 500 average of 2.74 and a discount versus the industry average of 4.95. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, INTUITIVE SURGICAL INC proves to trade at a discount to investment alternatives within the industry.
|ISRG 36.93||Peers 45.75||ISRG 26.25||Peers 28.28|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
ISRG is trading at a discount to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ISRG is trading at a valuation on par to its peers.
|ISRG 27.98||Peers 24.23||ISRG 0.87||Peers 0.89|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
ISRG is trading at a significant premium to its peers.
Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ISRG trades at a valuation on par to its peers.
|ISRG 4.78||Peers 4.95||ISRG 28.19||Peers 21.75|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ISRG is trading at a valuation on par with its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ISRG is expected to have an earnings growth rate that significantly exceeds its peers.
|ISRG 10.10||Peers 9.56||ISRG 13.46||Peers 18.83|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ISRG is trading at a valuation on par with its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ISRG significantly trails its peers on the basis of sales growth